The presentation, titled “The Alzheimer’s Journey: Reflections on What Matters Most to Patients, Caregivers, Physicians,” will shed new light on challenges people with Alzheimer’s face along their disease journey, explain how people living with Alzheimer’s and their families can become more empowered to make crucial decisions related to care, and highlight recent advancements in diagnosis and treatment. Panelists from TauRx and GT Diagnostics will deliver the presentation on 10 February at 10:30 GMT and will be on site at booth #2.
“Understanding the patient journey – particularly arriving at diagnosis, navigating complexities of caregiver and healthcare provider relationships, and making informed decisions when it comes to treatment – is of utmost importance to achieve optimal outcomes,” explains Richard Stefanacci, MD, Chief Medical Officer at TauRx. “We look forward to sharing insights at Dementias 2023 to drive the conversation toward better patient outcomes and discussing our progress in addressing this global unmet need.”
Alzheimer’s dementia is a leading cause of death throughout the world and one of the most important public health issues to be addressed globally. TauRx aims to contribute to addressing this unmet need with data from its Phase 3 LUCIDITY trial and pursuit of Medicines and Healthcare products Regulatory Agency (MHRA) approval through the Innovative Licensing and Access Pathway (ILAP), having been granted an Innovation Passport, the first stage of the process, in May 2022.
For additional information, please visit: https://taurx.com/ or https://www.dementiasconference.com/.
TauRx Pharmaceuticals Ltd. and GT Diagnostics will share key insights related to the AD patient journey during a presentation at the Dementias 2023 conference, London, 9-10 February 2023.
